Mofecet (Bupivacaine Hydrochloride Monohydrate)

Bupivacaine Hydrochloride Monohydrate, the active ingredient in Mofecet, is an amide‑type local anesthetic presented as a sterile injectable solution for intrathecal use. It provides regional nerve block for spinal, surgical and obstetric anesthesia. Mofecet is marketed in the European Union and is supplied in compliance with Good Distribution Practice.

GNH USA supplies Mofecet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mofecet is an amide‑type local anesthetic used in regional anesthesia and pain management.

- Spinal anesthesia: produces dense sensory and motor block for procedures requiring a regional block. - Surgical analgesia: offers prolonged postoperative pain relief after various surgical interventions. - Obstetric anesthesia: enables safe pain control during labor and cesarean delivery.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Hypotension: transient drop in blood pressure. - Bradycardia: slowed heart rate. - Nausea: mild to moderate upset stomach. - Dizziness: feeling of light‑headedness. - Headache: post‑dural puncture headache. - Transient motor weakness: temporary reduced muscle strength.

Serious or Rare Side Effects: - Cardiac arrhythmia: potentially life‑threatening rhythm disturbances. - Respiratory depression: reduced breathing effort. - Seizures: central nervous system excitation. - Prolonged nerve block: extended loss of sensation beyond intended duration. - Allergic reaction: rash, itching, or anaphylaxis. - Toxic plasma concentrations: systemic toxicity with neurological and cardiovascular signs.

Careful patient assessment and monitoring are essential when using intrathecal bupivacaine.

- Patient assessment: evaluate cardiac, hepatic and renal function before administration. - Dose calculation: ensure dose is individualized based on weight, age and clinical context. - Monitoring: continuously observe blood pressure, heart rate and respiratory status during and after injection. - Contraindications: avoid in patients with known hypersensitivity to amide‑type anesthetics. - Caution in cardiac disease: use reduced doses in patients with conduction abnormalities or heart failure. - Store at controlled room temperature: keep in original packaging, protect from light and moisture.

Bupivacaine may interact with other drugs that affect cardiac conduction or share metabolic pathways.

Major Interactions (Avoid): - Other local anesthetics: additive neuro‑ and cardiotoxicity. - Class I antiarrhythmics (e.g., quinidine): increased risk of arrhythmias. - Beta‑blockers: may exacerbate bradycardia and hypotension.

Moderate Interactions (Monitor Closely): - Calcium channel blockers: potential additive hypotensive effect. - Epinephrine: may potentiate systemic toxicity. - CYP3A4 inhibitors (e.g., ketoconazole): possible increased plasma levels. - Vasodilators: enhanced hypotensive response.